QuidelOrtho Corp

QuidelOrtho Corporation (NASDAQ: QDEL) is a global in vitro diagnostics company that develops, manufactures and markets a broad portfolio of diagnostic testing solutions across multiple healthcare settings. The company's vision is to advance diagnostics to power a healthier future through expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine. QuidelOrtho serves customers across more than 140 countries and territories, operating manufacturing facilities in the United States, United Kingdom and China, with sales centers and administrative offices distributed worldwide.

The company operates through five reportable geographic segments: North America, EMEA, China, JPAC and Latin America. Revenue is generated across four primary business units: Labs, which includes clinical chemistry and immunodiagnostics instruments and tests; Molecular Diagnostics, offering PCR-based testing platforms and infectious disease diagnostics; Point of Care, providing rapid diagnostic instruments and tests for professional and at-home use; and Transfusion Medicine, encompassing immunohematology and donor screening products. The company also generates non-core revenue through contract manufacturing and collaboration agreements.

QuidelOrtho maintains a portfolio of recognized diagnostic brands including VITROS, SOFIA, QUICKVUE, TRIAGE, ORTHO VISION and SAVANNA platforms. The company employs approximately 1,200 service professionals globally and maintains a commercial team exceeding 2,500 employees in sales, service and marketing functions. Its manufacturing operations benefit from vertically integrated proprietary processes and geographic diversity across multiple production facilities.

The company's business model centers on a "razor and razor blade" approach, wherein customers purchase instruments under long-term contracts and subsequently purchase assays, reagents and consumables, generating recurring revenue streams. QuidelOrtho differentiates itself through superior customer experience, strong commercial footprint, point-of-care leadership, manufacturing scale and supply chain resilience, and robust research and development capabilities. The company recently received the Excellence Services Label in its EMEA region, becoming the first medical device company to receive this ISO-sponsored distinction recognizing outstanding customer experience. QuidelOrtho's strategic focus emphasizes economic profit and return on invested capital across all business aspects while maintaining disciplined approaches to growth and capital allocation.